GET DAILY SIGNALSFulgent Genetics (FLGT) Narrows Losses in Q3 2026 as Pathology Revenue Rises
Key Takeaways
- Fulgent Genetics reported third quarter 2026 revenue of $90.4 million, ahead of the $86.3 million consensus estimate.
- Non-GAAP loss per share came in at $0.09, significantly better than the $0.65 consensus loss and the prior quarter's $0.58 loss.
- GAAP net loss narrowed to $13.2 million, or $0.48 per share, compared with a $29.5 million loss in the second quarter of 2026.
- Management reaffirmed full-year 2026 revenue guidance of $330 million to $340 million and improved its non-GAAP loss-per-share outlook to $1.65 to $1.75.
- Anatomic Pathology revenue grew 57% year over year, helping offset an 18% decline in Precision Diagnostics.
Why This Quarter Matters
FLGT has been working through a complex transition in its billing and revenue cycle management system, which affected collections and margins in recent quarters. The company is also integrating its 2026 acquisitions of Bako Diagnostics and StrataDx, which expand its Anatomic Pathology footprint. This quarter's report matters because it offers a direct read on whether those operational headwinds are easing and whether the acquired businesses are delivering the expected contribution. With the company still posting losses, investors are closely watching margin trajectory, cash position, and progress toward a return to profitability as key signals of the transformation's momentum. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What the Numbers Show
FLGT reported third quarter 2026 revenue of $90.4 million, topping the $86.3 million consensus estimate and rising from $85.4 million in the second quarter. The increase was driven primarily by the integration of Bako Diagnostics and StrataDx, which contributed $21.8 million to quarterly revenue.
On a GAAP basis, the company posted a net loss of $13.2 million, or $0.48 per share, a meaningful improvement from the prior quarter's $29.5 million loss. On a non-GAAP basis, which excludes equity-based compensation and intangible asset amortization, the loss was approximately $2.4 million, or $0.09 per share—far narrower than both the $0.65 consensus estimate and the prior quarter's $0.58 loss.
GAAP gross margin improved to 35.3%, while non-GAAP gross margin reached 36.3%, reflecting better collection rates and fixed-cost leverage on a higher revenue base. Adjusted EBITDA was a loss of approximately $7.5 million, compared with a $17.1 million loss in the prior quarter.
By segment, Precision Diagnostics generated $41.8 million (down 18% year over year), Anatomic Pathology contributed $40.9 million (up 57% year over year), and Biopharma Services added $7.7 million (up 5% year over year). The company ended the quarter with approximately $652.4 million in cash, equivalents, restricted cash, and marketable securities.
Market Reaction and Investor Sentiment
Heading into the report, investor sentiment around FLGT had been cautious, reflecting the ongoing revenue cycle transition, a prior full-year guidance reduction, and the loss of a large customer in the therapeutic development segment. The narrower-than-expected loss and a top-line beat provide evidence that the company's collection-rate challenges are beginning to ease. Still, the stock's longer-term performance has been pressured, and the market is likely to weigh the improved near-term execution against the fact that the company remains unprofitable on a GAAP basis. The improved non-GAAP loss guidance for 2026 is a notable positive signal, though investors will watch whether margin gains prove durable or simply reflect one-time bad-debt recoveries.
Forward Outlook and Key Factors to Monitor
Looking ahead, several factors will shape the investment narrative for FLGT. Management reaffirmed full-year 2026 revenue guidance of $330 million to $340 million and improved its non-GAAP loss-per-share outlook to $1.65 to $1.75, a meaningful upgrade from the prior range of $2.22 to $2.35. This suggests leadership expects the collection-rate recovery and cost discipline to continue into the fourth quarter.
Investors should monitor the completion of the remaining revenue cycle system customizations, since a return to historical collection rates would directly support margins. The integration of Bako Diagnostics and StrataDx remains another key watch item, as the acquired businesses are expected to contribute roughly $53 million in the second half of 2026.
The company's artificial intelligence initiatives also bear watching. Fulgent's AI platform analyzed approximately 255,000 slide images in the quarter, and management plans to deploy five additional AI applications in the fourth quarter, including a prostate cancer detection module. Finally, reimbursement dynamics—including potential changes under PAMA—and the therapeutic pipeline's progression will be important catalysts. A strong cash position of about $652.4 million provides financial flexibility as these initiatives unfold.
Enhancing Research with Tickeron’s AI Screener
In my view, Tickeron’s AI Screener has become a useful part of my routine when evaluating names like FLGT. It lets me quickly filter for technical patterns, fundamentals, and industry comparisons that help put the earnings picture in broader context. I find the customizable scans save time without replacing my own analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
FLGT sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for FLGT moved above the 200-day moving average on October 02, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +2.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where FLGT advanced for three days, in 188 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
FLGT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FLGT as a result. In 54 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for FLGT turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 37 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.
FLGT moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for FLGT crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FLGT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for FLGT entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.541) is normal, around the industry mean (66.911). P/E Ratio (-6.954) is within average values for comparable stocks, (2.514). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.013) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating fairly steady price growth. FLGT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FLGT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of genetic diagnostics services
Industry MedicalSpecialties
Advertisement